Carcinoma Cervix

---

Poor prognosis is seen in the following cancer type

---

A. Large cell non-keratinising
B. Small cell
C. Large cell keratinizing
D. Adenoma-malignum

---

---

The highest regional incidence and mortality rates with cancer cervix are seen in

---

A. North America
B. Australia/New Zealand
C. Western Asia
D. Sub-Saharan Africa

---

---

Not true of HPV infection is

---

A. HPV16 is the high risk type for cervical cancer
B. Risk of developing infection from high-risk HPV types is higher in women with HIV
C. Viral oncoproteins, E6 and E7 play a role in DNA methylation
D. Highest prevalence of HPV occurs at the age of 45 years

---

---

Not a risk factor for cervical cancer

---

A. OC pills
B. Circumcision
C. Smoking
D. High parity

---

---

Identification of HPV methylation site can be effectively done by

---

A. (RT)-PCR
B. NGS assays
C. Artificial intelligence (AI) based cytology
D. Hybrid Capture II ( HC2)

---

---

Treatment of choice for cancer cervix stage IB1 is

A. Simple hysterectomy
B. Radical Hysterectomy
C. RH with pelvic lymph node dissection
D. RH with pelvic lymph node dissection and radiotherapy

---

---

In short

---

• Types of radiation therapy currently used to treat cervical cancer are external beam radiation therapy (EBRT), intensity-modulated radiotherapy (IMRT), and brachytherapy (internal RT).

• The most effective single agent which has been used for the last three decades to treat cervical cancer is the platinum-based chemotherapeutic, cisplatin. Currently, topotecan, paclitaxel and other non-platinum-based chemotherapeutics such as 5-fluorouracil and bleomycin, are commonly used in combination with cisplatin for treating cervical cancer.

• EGFR is overexpressed in approximately 70% of cervical squamous cell carcinomas where it regulates growth, survival, proliferation, and differentiation

• Promising genetic therapy for cervical cancer employs genetic approaches such as CRISPR/Cas9 and RNAi

---